A Three-part Study Parts I, II and III: Rising Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Subjects (Part I) and Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Subjects With Type 1 Diabetes Mellitus (Part II and Part III)
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2016
At a glance
- Drugs MK 2640 (Primary) ; Glucose; Insulin; Insulin aspart; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 18 Aug 2016 Status changed from active, no longer recruiting to completed.
- 29 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.
- 29 Jul 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Aug 2016.